Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpha-type-1-polarized dendritic cell vaccine
- Development stage
- Phase 2
- Lead developer
- Roswell Park Comprehensive Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
The alpha-type-1-polarized dendritic cell vaccine (αDC1) is an autologous cell-based cancer immunotherapy developed by Dr. Pawel Kalinski and colleagues. This vaccine consists of dendritic cells generated from a patient's own peripheral blood mononuclear cells and matured using a specialized cytokine cocktail containing IFN-alpha, polyinosinic:polycytidylic acid (poly-I:C), TNF-alpha, IL-1beta, and IFN-gamma. The αDC1 cells are characterized by three key features: a fully mature status, responsiveness to secondary lymphoid organ chemokines (CCR7 ligands), and high interleukin-12p70 (IL-12p70) production capacity. These dendritic cells are loaded with tumor-associated antigens, such as apoptotic autologous tumor cells, and administered to patients to induce potent cytotoxic T lymphocyte (CTL) responses. The vaccine aims to stimulate the patient's immune system to recognize and destroy tumor cells by promoting Type-1 immunity and enhancing CTL infiltration into tumor tissues.
- Other names
- alpha-type-1 dendritic cell vaccinealpha-type1 dendritic cell vaccinealpha-type 1 dendritic cell vaccineαDC1 vaccineautologous alpha-type-1-polarized dendritic cell vaccine
Beyond the preview
Go deeper on alpha-type-1-polarized dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alpha-type-1-polarized dendritic cell vaccine.